A systematic review of impulse control disorders in Parkinson's disease

Journal of Parkinson's Disease

Volumn 3, Issue 2, 2013, Pages 105-138

  Callesen, Mette Buhl ^a,b   Scheel Krüger, Jørgen ^b   Kringelbach, Morten L ^b,c   Møller, Arne ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

decision making; dopamine; Impulse control disorders; neuroanatomy; Parkinson disease; serotonin

Indexed keywords

AMANTADINE; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE;

BINGE EATING DISORDER; BOLD SIGNAL; COMORBIDITY; COMPULSIVE BUYING; DECISION MAKING; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINE DYSREGULATION SYNDROME; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FRONTAL CORTEX; GEOGRAPHIC DISTRIBUTION; HOBBYISM; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; INCIDENCE; MEDICAL LITERATURE; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PREVALENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PUNDING; REINFORCEMENT; REVIEW; SUBTHALAMIC NUCLEUS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

HUMANS; IMPULSIVE BEHAVIOR; PARKINSON DISEASE;

EID: 84880175119     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-120165     Document Type: Review

References (227)

1. Parkinson J (1817) An Essay on the Shaking Palsy.
2. Rowe JB, Hughes L, Ghosh BC, Eckstein D,Williams-Gray CH, Fallon S, Barker RA, & Owen AM (2008) Parkinson's disease and dopaminergic therapy-differential effects on movement, reward and cognition. Brain, 131(Pt 8), 2094-2105.
3. Cools R (2006) Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev, 30(1), 1-23.
4. Cools R, Frank MJ, Gibbs SE, Miyakawa A, Jagust W, & D'Esposito M (2009) Striatal dopamine predicts outcomespecific reversal learning and its sensitivity to dopaminergic drug administration. J Neurosci, 29(5), 1538-1543.
5. Brand M, Labudda K, Kalbe E, Hilker R, Emmans D, Fuchs G, Kessler J, & Markowitsch HJ (2004) Decision-making impairments in patients with Parkinson's disease. Behav Neurol, 15(3-4), 77-85.
6. Gleichgerrcht E, Ibanez A, Roca M, Torralva T, & Manes F (2010) Decision-making cognition in neurodegenerative diseases. Nat Rev Neurol, 6(11), 611-623.
7. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, & Obeso JA (2009) Initial clinical manifestations of Parkinson's disease: Features and pathophysiological mechanisms. Lancet Neurol, 8(12), 1128-1139.
8. Weintraub D, & Nirenberg MJ (2012) Impulse Control and Related Disorders in Parkinson's Disease. Neurodegener Dis, 11(2), 63-71.
9. Tang J, Strafella AP (2012) The frontostriatal circuitry and behavioral complications in PD. Parkinsonism & related disorders, 18(Suppl 1), S104-S106.
10. Kano O, Ikeda K, Cridebring D, Takazawa T, Yoshii Y, & Iwasaki Y (2011) Neurobiology of depression and anxiety in Parkinson's disease. Parkinsons Dis, 2011, 143547.
11. Bonnet AM, Jutras MF, Czernecki V, Corvol JC, & Vidailhet M (2012) Nonmotor symptoms in Parkinson's disease in 2012: Relevant clinical aspects. Parkinsons Dis, 2012, 198316.
12. Dubois B, & Pillon B (1997) Cognitive deficits in Parkinson's disease. Journal of Neurology, 244(1), 2-8.
13. Hirano S, Shinotoh H, & Eidelberg D (2012) Functional brain imaging of cognitive dysfunction in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 83(10), 963-969.
14. Crossman AR (1990) A hypothesis on the pathophysiological mechanisms that underlie levodopa-or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment.Movement Disorders: Official Journal of the Movement Disorder Society, 5(2), 100-108.
15. APAAPA(1994) Diagnostic and Statistical Manual of Mental Disorders, Fourth Revision (DSM-IV).Washington DC: American Psychiatric Association.
16. Seedat S,Kesler S, Niehaus DJ,&Stein DJ (2000) Pathological gambling behaviour: Emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety, 11(4), 185-186.
17. Weintraub D, Papay K, & Siderowf A (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control study. Neurology, 80(2), 176-180.
18. Molina JA, Sainz-ArtigaMJ, Fraile A, Jimenez-Jimenez FJ, Villanueva C, Orti-ParejaM,&Bermejo F (2000) Pathologic gambling in Parkinson's disease: A behavioral manifestation of pharmacologic treatment? Mov Disord, 15(5), 869-872.
19. Avanzi M, Uber E, & Bonfa F (2004) Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci, 25(2), 98-101.
20. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, & Ahlskog JE (2005) Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol, 62(9), 1377-1381.
21. Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, & Bonfa F (2006) Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord, 21(12), 2068-2072.
22. Weintraub D, & Potenza MN (2006) Impulse control disorders in Parkinson's disease. Curr Neurol Neurosci Rep, 6(4), 302-306.
23. Moro E (2009) Impulse control disorders and subthalamic nucleus stimulation in Parkinson's disease: Are we jumping the gun? Eur J Neurol, 16(4), 440-441.
24. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, Lang AE, & Miyasaki J (2006) Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology, 67(7), 1254-1257.
25. Voon V, Thomsen T, Miyasaki JM, de Souza M, Shafro A, Fox SH, Duff-Canning S, Lang AE, & Zurowski M (2007) Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol, 64(2), 212-216.
26. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, & Lang AE Impulse control disorders in Parkinson disease: A crosssectional study of 3090 patients. Arch Neurol, 67(5), 589-595.
27. Kim J, Kim M,KwonDY, Seo WK, Kim JH, Baik JS,&Koh SB (2012) Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease. Journal of neurology, 260(2), 429-437.
28. Poletti M, & Bonuccelli U (2012) Impulse control disorders in Parkinson' disease: The role of personality and cognitive status. Journal of Neurology, 259(11), 2269-2277.
29. Potenza MN, Kosten TR, & Rounsaville BJ (2001) Pathological gambling. JAMA, 286(2), 141-144.
30. Dagher A, & Robbins TW: (2009) Personality addiction, dopamine: Insights from Parkinson's disease. Neuron, 61(4), 502-510.
31. TemelY, Blokland A, SteinbuschHW,&Visser-Vandewalle V (2005) The functional role of the subthalamic nucleus in cognitive and limbic circuits. Prog Neurobiol, 76(6), 393-413.
32. Moum SJ, Price CC, Limotai N, Oyama G, Ward H, Jacobson C, Foote KD, & Okun MS (2012) Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One, 7(1), e29768.
33. Romito LM, Raja M, Daniele A, Contarino MF, Bentivoglio AR, Barbier A, Scerrati M, & Albanese A (2002) Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Movement disorders: Official Journal of the Movement Disorder Society, 17(6), 1371-1374.
34. Sriram A,Ward HE, Hassan A, Iyer S, Foote KD, Rodriguez RL, McFarland NR, & Okun MS (2012) Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. Journal of Neurology, 260(2), 521-527.
35. Witjas T, Baunez C, Henry JM, Delfini M, Regis J, Cherif AA, Peragut JC, & Azulay JP (2005) Addiction in Parkinson's disease: Impact of subthalamic nucleus deep brain stimulation. Mov Disord, 20(8), 1052-1055.
36. Zahodne LB, Susatia F, Bowers D, Ong TL, Jacobson CEt, Okun MS, Rodriguez RL, Malaty IA, Foote KD, & Fernandez HH (2011) Binge eating in Parkinson's disease: Prevalence, correlates and the contribution of deep brain stimulation. The Journal of Neuropsychiatry and Clinical Neurosciences, 23(1), 56-62.
37. Smeding HM, Goudriaan AE, Foncke EM, Schuurman PR, Speelman JD, & Schmand B (2007) Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry, 78(5), 517-519.
38. Rodriguez-Oroz MC, Lopez-Azcarate J, Garcia-Garcia D, Alegre M, Toledo J, Valencia M, Guridi J, Artieda J, & Obeso JA (2011) Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain: A journal of neurology, 134(Pt 1), 36-49.
39. Lim SY, O'Sullivan SS, Kotschet K, Gallagher DA, Lacey C, Lawrence AD, Lees AJ, O'Sullivan DJ, Peppard RF, Rodrigues JP, et al. (2009) Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci, 16(9), 1148-1152.
40. Knobel D, Aybek S, Pollo C, Vingerhoets FJ, & Berney A (2008) Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): A case report. Cognitive and Behavioral Neurology: Official Journal of the Society for Behavioral and Cognitive Neurology, 21(3), 187-189.
41. Bandini F, Primavera A, Pizzorno M, & Cocito L (2007) Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord, 13(6), 369-371.
42. Halbig TD, Tse W, Frisina PG, Baker BR, Hollander E, Shapiro H, Tagliati M, Koller WC, & Olanow CW (2009) Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol, 16(4), 493-497.
43. Robert G, Drapier D, Verin M, Millet B, Azulay JP, & Blin O (2009) Cognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology. Movement Disorders: Official Journal of the Movement Disorder Society, 24(16), 2316-2327.
44. Frank MJ, Samanta J, Moustafa AA, & Sherman SJ (2007) Hold your horses: Impulsivity, deep brain stimulation, and medication in parkinsonism. Science, 318(5854), 1309-1312.
45. VoonV, Gao J, Brezing C, Symmonds M, EkanayakeV, Fernandez H, Dolan RJ,&HallettM(2011) Dopamine agonists and risk: Impulse control disorders in Parkinson's disease. Brain: A Journal of Neurology, 134(Pt 5), 1438-1446.
46. GallagherDA, O'Sullivan SS, Evans AH, Lees AJ,&Schrag A(2007) Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord, 22(12), 1757-1763.
47. Wu K, Politis M, & Piccini P (2009) Parkinson disease and impulse control disorders: A review of clinical features, pathophysiology and management. Postgrad Med J, 85(1009), 590-596.
48. Singh A, Kandimala G, Dewey RB Jr & O'Suilleabhain P (2007) Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci, 14(12), 1178-1181.
49. Delaney M, Leroi I, Simpson J, & Overton PG (2012) Impulse control disorders in Parkinson's disease: A psychosocial perspective. J Clin Psychol Med Settings, 19(3), 338-346.
50. Lee JY, Jeon BS, Kim HJ, & Park SS (2012) Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism & related disorders, 18(1), 76-78.
51. Claassen DO, van den Wildenberg WP, Ridderinkhof KR, Jessup CK, Harrison MB, Wooten GF, & Wylie SA (2011) The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav Neurosci, 125(4), 492-500.
52. Cormier F, Muellner J, & Corvol JC (2012) Genetics of impulse control disorders in Parkinson's disease. Journal of Neural Transmission, 120(4), 665-671.
53. Weiss HD, Hirsch ES,Williams JR, Swearengin L,&Marsh L(2010) Detection of impulse control disorders in Parkinson disease patients. The Neurologist, 16(6), 406-407.
54. Joutsa J, Martikainen K, Vahlberg T, Voon V, & Kaasinen V (2012) Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism & Related Disorders, 18(2), 155-160.
55. Joutsa J, Martikainen K, Vahlberg T, Kaasinen V (2012) Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Parkinsonism & Related Disorders, 18(10), 1079-1083.
56. Tokunaga N, Choudhury ME, Nishikawa N, Nagai M, Tujii T, Iwaki H, Kaneta M, & Nomoto M (2012) Pramipexole upregulates dopamine receptor D(2) and D(3) expression in rat striatum. J Pharmacol Sci, 120(2), 133-137.
57. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, & Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry, 68(4), 423-428.
58. Gschwandtner U, Aston J, Renaud S,&Fuhr P (2001) Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol, 24(3), 170-172.
59. Driver-Dunckley E, Samanta J,&StacyM(2003) Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology, 61(3), 422-423.
60. Kurlan R (2004) Disabling repetitive behaviors in Parkinson's disease. Mov Disord, 19(4), 433-437.
61. Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, Lawrence AD, & Lees AJ (2004) Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome. Mov Disord, 19(4), 397-405.
62. Klos KJ, Bower JH, Josephs KA, Matsumoto JY,&Ahlskog JE (2005) Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord, 11(6), 381-386.
63. Larner AJ (2006) Medical hazards of the internet: Gambling in Parkinson's disease. Mov Disord, 21(10), 1789.
64. Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V, Hosseini H, Pelissolo A, Moro E, Lhommee E, Lang AE et al. (2006): Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord, 21(11), 1941-1946.
65. Grosset KA, Macphee G, Pal G, Stewart D,Watt A, Davie J, & Grosset DG (2006) Problematic gambling on dopamine agonists: Not such a rarity. Mov Disord, 21(12), 2206-2208.
66. Drapier D, Drapier S, Sauleau P, Derkinderen P, Damier P, Allain H,Verin M,&Millet B (2006) Pathological gambling secondary to dopaminergic therapy in Parkinson's disease. Psychiatry Res, 144(2-3), 241-244.
67. Imamura A, Uitti RJ, & Wszolek ZK (2006) Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism Relat Disord, 12(8), 506-508.
68. Voon V, & Fox SH (2007) Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol, 64(8), 1089-1096.
69. Giladi N, Weitzman N, Schreiber S, Shabtai H, & Peretz C (2007) New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: The role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol, 21(5), 501-506.
70. Wong SH, Cowen Z, Allen EA, & Newman PK (2007) Internet gambling and other pathological gambling in Parkinson's disease: A case series. Mov Disord, 22(4), 591-593.
71. McKeon A, Josephs KA, Klos KJ, Hecksel K, Bower JH, Michael Bostwick J, & Eric Ahlskog J (2007) Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord, 13(8), 516-519.
72. Ondo WG, & Lai D (2008) Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord, 14(1), 28-32.
73. Crockford D, Quickfall J, Currie S, Furtado S, Suchowersky O, & El-Guebaly N (2008) Prevalence of problem and pathological gambling in Parkinson's disease. J Gambl Stud, 24(4), 411-422.
74. Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Van Eimeren T, Rusjan P, Houle S,&Strafella AP (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: A [11C] raclopride PET study. Brain, 132(Pt 5), 1376-1385.
75. Voon V, Reynolds B, Brezing C, Gallea C, Skaljic M, Ekanayake V, Fernandez H, Potenza MN, Dolan RJ, & Hallett M (2010) Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology (Berl), 207(4), 645-659.
76. Wylie SA, Ridderinkhof KR, Elias WJ, Frysinger RC, Bashore TR,Downs KE, vanWouwe NC,&van denWildenbergWP (2010) Subthalamic nucleus stimulation influences expression and suppression of impulsive behaviour in Parkinson's disease. Brain: A Journal of Neurology, 133(Pt 12), 3611-3624.
77. Vergani F, Landi A, Pirillo D, Cilia R, Antonini A,&Sganzerla EP (2010) Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease. World Neurosurg, 73(4), 338-344.
78. Vitale C, Santangelo G,Trojano L,Verde F, Rocco M, Grossi D, & Barone P (2011) Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson's disease. Movement disorders: Official journal of the Movement Disorder Society, 26(5), 830-836.
79. Evans AH, Pavese N, Lawrence AD, TaiYF, Appel S, Doder M, Brooks DJ, Lees AJ,&Piccini P (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Annals of Neurology, 59(5), 852-858.
80. Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, Weintraub D, Wunderlich GR, & Stacy M (2011) Impulse control disorders in Parkinson disease: A multicenter case-control study. Annals of Neurology, 69(6), 986-996.
81. Giugni JC, Tschopp L, Escalante V, & Micheli F (2012) Dose-dependent impulse control disorders in piribedil overdose. Clinical Neuropharmacology, 35(1), 49-50.
82. Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, Antonelli F, Houle S, Lang AE, & Strafella AP (2012) Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medicationinduced pathological gambling: A [11C] FLB-457 and PET study. Neurobiol Dis, 48(3), 519-525.
83. Limotai N, Oyama G, Go C, Bernal O, Ong T, Moum SJ, Bhidayasiri R, Foote KD, Bowers D, Ward H, et al. (2012) Addiction-like manifestations and Parkinson's disease: A large single center 9-year experience. Int J Neurosci, 122(3), 145-153.
84. Avila A, Cardona X, Martin-Baranera M, Bello J,&Sastre F (2011) Impulsive and compulsive behaviors in Parkinson's disease:Aone-year follow-up study. J Neurol Sci, 310(1-2), 197-201.
85. Auyeung M, Tsoi TH, Tang WK, Cheung CM, Lee CN, Li R, & Yeung E (2011) Impulse control disorders in Chinese Parkinson's disease patients: The effect of ergot derived dopamine agonist. Parkinsonism & Related Disorders, 17(8), 635-637.
86. Leroi I, Ahearn DJ, Andrews M, McDonald KR, Byrne EJ,& Burns A (2011) Behavioural disorders, disability and quality of life in Parkinson's disease. Age Ageing, 40(5), 614-621.
87. Biundo R, Formento-Dojot P, Facchini S, Vallelunga A, Ghezzo L, Foscolo L, Meneghello F, & Antonini A (2011) Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci, 310(1-2), 64-69.
88. Spengos K, Grips E, Karachalios G, Tsivgoulis G, & Papadimitriou G (2006) Reversible pathological gambling under treatment with pramipexole. Nervenarzt, 77(8), 958-960.
89. Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern MB, & Weintraub D (2008) Long-term follow-up of impulse control disorders in Parkinson's disease. Movement disorders: Official Journal of the Movement Disorder Society, 23(1), 75-80.
90. Weintraub D, Siderowf AD, PotenzaMN,Goveas J, Morales KH, Duda JE, Moberg PJ, & Stern MB (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Archives of Neurology, 63(7), 969-973.
91. Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G, & Antonini A (2008) The relationship between impulsivity and impulse control disorders in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 23(3), 411-415.
92. Rao H, Mamikonyan E, Detre JA, Siderowf AD, Stern MB, Potenza MN, &Weintraub D (2010) Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 25(11), 1660-1669.
93. Sensi M, Eleopra R, Cavallo MA, Sette E, Milani P, Quatrale R, Capone JG, Tugnoli V, Tola MR, Granieri E, et al. (2004) Explosive-aggressive behavior related to bilateral subthalamic stimulation. Parkinsonism Relat Disord, 10(4), 247-251.
94. Cilia R, Cho SS, van Eimeren T, Marotta G, Siri C, Ko JH, Pellecchia G, Pezzoli G, Antonini A, & Strafella AP (2011) Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection:Apath modeling analysis. Movement Disorders: Official Journal of the Movement Disorder Society, 26(2), 225-233.
95. Cilia R, Ko JH, Cho SS, van Eimeren T, Marotta G, Pellecchia G, Pezzoli G, Antonini A, & Strafella AP (2010) Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis, 39(1), 98-104.
96. Voon V, Pessiglione M, Brezing C, Gallea C, Fernandez HH, Dolan RJ, & HallettM(2010) Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron, 65(1), 135-142.
97. Bentivoglio AR, Baldonero E, Ricciardi L, De Nigris F, & Daniele A (2012) Neuropsychological features of patients with Parkinson's disease and impulse control disorders. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
98. Pezzella FR, Colosimo C, Vanacore N, Di Rezze S, Chianese M, Fabbrini G, & Meco G (2005) Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord, 20(1), 77-81.
99. Lim SY, Tan ZK, Ngam PI, Lor TL, Mohamed H, Schee JP, Tan AK, Goh JY, Ooi E, & Soh PC (2011) Impulsivecompulsive behaviors are common in Asian Parkinson's disease patients: Assessment using the QUIP. Parkinsonism & Related Disorders, 17(10), 761-764.
100. Bastiaens J, Dorfman BJ, Christos PJ, & Nirenberg MJ (2013) Prospective cohort study of impulse control disorders in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 28(3), 327-333.
101. Vitale C, Santangelo G, Erro R, Errico D, Manganelli F, Improta I, Moccia M, & Barone P (2013) Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: Report of 2 cases. Parkinsonism & Related Disorders, 19(4), 483-484.
102. Hinnell C, Hulse N, Martin A, & Samuel M (2011) Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy. Parkinsonism & Related Disorders, 17(4), 295-296.
103. Solla P, Cannas A, Marrosu MG, & Marrosu F (2012) Dopaminergic-induced paraphilias associated with impulse control and related disorders in patients with Parkinson disease. Journal of Neurology, 259(12), 2752-2754.
104. Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, & Rascol O (2012) Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clinical Neuropharmacology, 35(6), 261-265.
105. Joutsa J, Martikainen K, Niemela S, Johansson J, Forsback S, Rinne JO, & Kaasinen V (2012) Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Movement Disorders: Official Journal of the Movement Disorder Society, 27(6), 778-782.
106. Weintraub D, Xie S, Karlawish J, & Siderowf A (2007) Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: Evidence from the 15-item Geriatric Depression Scale (GDS-15). International Journal of Geriatric Psychiatry, 22(10), 1025-1030.
107. van Eimeren T, Pellecchia G, Cilia R, Ballanger B, Steeves TD, Houle S, Miyasaki JM, Zurowski M, Lang AE, & Strafella AP (2010) Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology, 75(19), 1711-1716.
108. Cilia R, Siri C, Marotta G, Isaias IU, De Gaspari D, Canesi M, Pezzoli G, & Antonini A (2008) Functional abnormalities underlying pathological gambling in Parkinson disease. Archives of Neurology, 65(12), 1604-1611.
109. de Chazeron I, Llorca PM, Chereau-Boudet I, Blanc O, Perriot J, Ouchchane L, Ulla M, Debilly B, Derost P, & Durif F (2011) Hypersexuality and pathological gambling in Parkinson's disease: A cross-sectional case-control study. Movement Disorders: Official Journal of the Movement Disorder Society, 26(11), 2127-2130.
110. Wu K, O'Sullivan S, Politis M, Bose S, Lees A, & Piccini P (2010) Rewarding visual cues increase dopamine neurotransmission in Parkinspn's patients with impulse control disorders: A PET study. J Neurol Neurosurg Psychiatry, 81, e29-e30.
111. O'Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, Djamshidian A, Lees AJ, & Piccini P (2011) Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain: A Journal of Neurology, 134(Pt 4), 969-978.
112. Frosini D, Pesaresi I, Cosottini M, Belmonte G, Rossi C, Dell'Osso L, Murri L, Bonuccelli U, & Ceravolo R (2010) Parkinson's disease and pathological gambling: Results from a functional MRI study. Movement Disorders: Official Journal of the Movement Disorder Society, 25(14), 2449-2453.
113. Djamshidian A, O'Sullivan SS, Sanotsky Y, Sharman S, Matviyenko Y, Foltynie T, Michalczuk R, Aviles-Olmos I, Fedoryshyn L, Doherty KM et al. (2012) Decision making, impulsivity, and addictions: Do Parkinson's disease patients jump to conclusions? Movement Disorders: Official Journal of the Movement Disorder Society, 27(9), 1137-1145.
114. Siri C, Cilia R, De Gaspari D, Canesi M, Meucci N, Zecchinelli AL, Pezzoli G, & Antonini A (2010) Cognitive status of patients with Parkinson's disease and pathological gambling. Journal of Neurology, 257(2), 247-252.
115. Kimber TE, Thompson PD, & KileyMA (2008) Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia, 15(2), 205-208.
116. Tschopp L, Salazar Z, Gomez Botello MT, Roca CU, & Micheli F (2010) Impulse control disorder and piribedil: Report of 5 cases. Clinical Neuropharmacology, 33(1), 11-13.
117. Wingo TS, Evatt M, Scott B, Freeman A, & StacyM(2009) Impulse control disorders arising in 3 patients treated with rotigotine. Clinical Neuropharmacology, 32(2), 59-62.
118. Stefani A, Galati S, Brusa L, Pierantozzi M, Peppe A, & Stanzione P (2010) Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine. BMJ Case Rep, 2010.
119. Ferńandez FM, & Gonźalez TM (2009) Pathological gambling and hypersexuality due to dopaminergic treatment in Parkinson's disease. Actas Esp Psiquiatr, 37(2), 118-122.
120. Cooper CA, Jadidian A, Paggi M, Romrell J, Okun MS, Rodriguez RL, & Fernandez HH (2009) Prevalence of hypersexual behavior in Parkinson's disease patients: Not restricted to males and dopamine agonist use. Int J Gen Med, 2, 57-61.
121. Bharmal A, Lu C, Quickfall J, Crockford D,&Suchowersky O (2010) Outcomes of patients with Parkinson disease and pathological gambling. Can J Neurol Sci, 37(4), 473-477.
122. Imamura A, Geda YE, Slowinski J, Wszolek ZK, Brown LA,&Uitti RJ (2008) Medications used to treat Parkinson's disease and the risk of gambling. Eur J Neurol, 15(4), 350-354.
123. Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, & Barone P (2009) Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 24(6), 899-905.
124. Kolla BP, Mansukhani MP, Barraza R, & Bostwick JM (2010) Impact of dopamine agonists on compulsive behaviors: A case series of pramipexole-induced pathological gambling. Psychosomatics, 51(3), 271-273.
125. Kenangil G, Ozekmekci S, Sohtaoglu M, & Erginoz E (2010) Compulsive behaviors in patients with Parkinson's disease. The neurologist, 16(3), 192-195.
126. Bonfanti AB, & Gatto EM (2010) Kleptomania, an unusual impulsive control disorder in Parkinson's disease? Parkinsonism & Related Disorders, 16(5), 358-359.
127. Wicks P, & MacPhee GJ (2009) Pathological gambling amongst Parkinson's disease and ALS patients in an online community (PatientsLikeMe.com) . Movement Disorders: Official Journal of the Movement Disorder Society, 24(7), 1085-1088.
128. Fan W, Ding H, Ma J, & Chan P (2009) Impulse control disorders in Parkinson's disease in a Chinese population. Neurosci Lett, 465(1), 6-9.
129. Lee JY, Kim JM, Kim JW, Cho J, Lee WY, Kim HJ, & Jeon BS (2010) Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism & Related Disorders, 16(3), 202-207.
130. Hassan A, Bower JH, Kumar N, Matsumoto JY, Fealey RD, Josephs KA, & Ahlskog JE (2011) Dopamine agonisttriggered pathological behaviors: Surveillance in the PD clinic reveals high frequencies. Parkinsonism & Related Disorders, 17(4), 260-264.
131. Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, & Lang AE (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Annals of Neurology, 68(6), 963-968.
132. Serrano-DuenasM(2002) Chronic dopaminetic drug addiction and pathological gambling in patients with Parkinson's disease-presentation of four cases. German J Psychiatry, 5, 62-66.
133. Cilia R, & van Eimeren T (2011) Impulse control disorders in Parkinson's disease: Seeking a roadmap toward a better understanding. Brain Struct Funct, 216(4), 289-299.
134. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, & Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 25(15), 2649-2653.
135. Mallet L, Schupbach M, N'Diaye K, Remy P, Bardinet E, Czernecki V,Welter ML, Pelissolo A, RubergM, Agid Y, et al. (2007) Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci USA, 104(25), 10661-10666.
136. Rogers RD,Wielenberg B,Wojtecki L, Elben S, Campbell-Meiklejohn D,&SchnitzlerA(2011) Deep brain stimulation of the subthalamic nucleus transiently enhances losschasing behaviour in patients with Parkinson's disease. Exp Neurol, 231(1), 181-189.
137. Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H, Chabardes S, Foote K, Benabid AL, & Pollak P (2004) Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 75(6), 834-839.
138. Volkmann J, Daniels C, & Witt K (2010) Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol, 6(9), 487-498.
139. Adam R, Leff A, Sinha N, Turner C, Bays P, Draganski B, & HusainM(2012) Dopamine reverses reward insensitivity in apathy following globus pallidus lesions. Cortex, 49(5), 1292-1303.
140. Leroi I, Andrews M, McDonald K, Harbishettar V, Elliott R, Byrne EJ, & Burns A (2012) Apathy and impulse control disorders in Parkinson's disease: A direct comparison. Parkinsonism & Related Disorders, 18(2), 198-203.
141. Ahearn DJ, McDonald K, Barraclough M, & Leroi I (2012) An exploration of apathy and impulsivity in Parkinson disease. Curr Gerontol Geriatr Res, 2012, 390701.
142. Jenkinson N, Nandi D, Muthusamy K, Ray NJ, Gregory R, Stein JF, & Aziz TZ (2009) Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. Movement Disorders: Official Journal of the Movement Disorder Society, 24(3), 319-328.
143. Androulidakis AG,Mazzone P, Litvak V, PennyW, Dileone M, Gaynor LM, Tisch S, Di Lazzaro V, & Brown P (2008) Oscillatory activity in the pedunculopontine area of patients with Parkinson's disease. Exp Neurol, 211(1), 59-66.
144. Thevathasan W, Silburn PA, Brooker H, Coyne TJ, Khan S, Gill SS, Aziz TZ, & Brown P (2010) The impact of low-frequency stimulation of the pedunculopontine nucleus region on reaction time in parkinsonism. Journal of Neurology, Neurosurgery, and Psychiatry, 81(10), 1099-1104.
145. Okada K, Toyama K, Inoue Y, Isa T, & Kobayashi Y (2009) Different pedunculopontine tegmental neurons signal predicted and actual task rewards. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 29(15), 4858-4870.
146. Kobayashi Y, & Okada K (2007) Reward prediction error computation in the pedunculopontine tegmental nucleus neurons. Ann N Y Acad Sci, 1104, 310-323.
147. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, Jayne M, Ma Y, & Wong C (2006) Cocaine cues and dopamine in dorsal striatum: Mechanism of craving in cocaine addiction. The Journal of neuroscience: The Official Journal of the Society for Neuroscience, 26(24), 6583-6588.
148. Cools R, Lewis SJ, Clark L, Barker RA, & Robbins TW (2007) L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 32(1), 180-189.
149. Voon V, & Dalley JW (2011) Parkinson disease: Impulsive
150. Graef S, Biele G, Krugel LK, Marzinzik F, Wahl M, Wotka J, Klostermann F, & Heekeren HR (2010) Differential influence of levodopa on reward-based learning in Parkinson's disease. Front Hum Neurosci, 4, 169.
151. Linnet J, Moller A, Peterson E, Gjedde A, & Doudet D (2011) Dopamine release in ventral striatum during Iowa Gambling Task performance is associated with increased excitement levels in pathological gambling. Addiction, 106(2), 383-390.
152. Linnet J, Peterson E, Doudet DJ, Gjedde A, & Moller A (2010) Dopamine release in ventral striatum of pathological gamblers losing money. Acta Psychiatr Scand, 122(4), 326-333.
153. Peterson E, Moller A, Doudet DJ, Bailey CJ, Hansen KV, Rodell A, Linnet J, & Gjedde A (2010) Pathological gambling: Relation of skin conductance response to dopaminergic neurotransmission and sensation-seeking. Eur Neuropsychopharmacol, 20(11), 766-775.
154. de Ruiter MB, Veltman DJ, Goudriaan AE, Oosterlaan J, Sjoerds Z, & van den Brink W (2009) Response perseveration and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 34(4), 1027-1038.
155. Reuter J, Raedler T, Rose M, Hand I, Glascher J, & Buchel C (2005) Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nature Neuroscience, 8(2), 147-148.
156. Nader MA, Morgan D, Gage HD, Nader SH, Calhoun TL, Buchheimer N, Ehrenkaufer R, & Mach RH (2006) PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nature Neuroscience, 9(8), 1050-1056.
157. Volkow ND, Fowler JS, & Wang GJ (2002) Role of dopamine in drug reinforcement and addiction in humans: Results from imaging studies. Behav Pharmacol, 13(5-6), 355-366.
158. Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Laane K, Pena Y, Murphy ER, Shah Y, Probst K, et al. (2007) Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science, 315(5816), 1267-1270.
159. Volkow ND, Wang GJ, Telang F, Fowler JS, Thanos PK, Logan J, Alexoff D, Ding YS, Wong C, Ma Y, et al. (2008) Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: Possible contributing factors. Neuroimage, 42(4), 1537-1543.
160. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, ZhuW, Netusil N, & Fowler JS (2001) Brain dopamine and obesity. Lancet, 357(9253), 354-357.
161. Volkow ND, Fowler JS, Wang GJ, & Goldstein RZ (2002) Role of dopamine, the frontal cortex and memory circuits in drug addiction: Insight from imaging studies. Neurobiol Learn Mem, 78(3), 610-624.
162. Joutsa J, Johansson J, Niemela S, Ollikainen A, Hirvonen MM, Piepponen P, Arponen E, Alho H,VoonV, Rinne JO, et al. (2012) Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage, 60(4), 1992-1999.
163. Kringelbach ML,&BerridgeKC(2010) The functional neuroanatomy of pleasure and happiness. Discov Med, 9(49), 579-587.
164. Berridge KC (2007) The debate over dopamine's role in reward: The case for incentive salience. Psychopharmacology (Berl), 191(3), 391-431.
165. Everitt BJ, & Robbins TW (2005) Neural systems of reinforcement for drug addiction: From actions to habits to compulsion. Nature Neuroscience, 8(11), 1481-1489.
166. Haber SN, & Knutson B (2010) The reward circuit: Linking primate anatomy and human imaging. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 35(1), 4-26.
167. Voon V, Mehta AR, & Hallett M (2011) Impulse control disorders in Parkinson's disease: Recent advances. Current Opinion in Neurology, 24(4), 324-330.
168. Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, & Di Giovanni G (2008) Serotonin modulation of the basal ganglia circuitry: Therapeutic implication for Parkinson's disease and other motor disorders. Prog Brain Res, 172, 423-463.
169. Cools R (2008) Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist, 14(4), 381-395.
170. Cools R, Nakamura K, & Daw ND (2011) Serotonin and dopamine: Unifying affective, activational, and decision functions. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 36(1), 98-113.
171. Rogers RD (2011) The roles of dopamine and serotonin in decision making: Evidence from pharmacological experiments in humans. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 36(1), 114-132.
172. Robinson ES, Dalley JW, Theobald DE, Glennon JC, Pezze MA, Murphy ER,&RobbinsTW(2008) Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacology, 33(10), 2398-2406.
173. Homberg JR (2012) Serotonin and decision making processes. Neuroscience and Biobehavioral Reviews, 36(1), 218-236.
174. Kirby LG, Zeeb FD,&Winstanley CA(2011) Contributions of serotonin in addiction vulnerability. Neuropharmacology, 61(3), 421-432.
175. Macoveanu J, Rowe JB, Hornboll B, Elliott R, Paulson OB, Knudsen GM, & Siebner HR (2012) Playing it safe but losing anyway-Serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion. Eur Neuropsychopharmacol, in press.
176. Miyazaki K, Miyazaki KW, & Doya K (2012) The role of serotonin in the regulation of patience and impulsivity. Mol Neurobiol, 45(2), 213-224.
177. Campbell-Meiklejohn D, Wakeley J, Herbert V, Cook J, Scollo P, Ray MK, Selvaraj S, Passingham RE, Cowen P, & Rogers RD (2011) Serotonin and dopamine play complementary roles in gambling to recover losses. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 36(2), 402-410.
178. Long AB, Kuhn CM, & Platt ML (2009) Serotonin shapes risky decision making in monkeys. Soc Cogn Affect Neurosci, 4(4), 346-356.
179. Chung SK, You IH, Cho GH, Chung GH, Shin YC, Kim DJ, & Choi SW (2009) Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J, 50(3), 441-444.
180. Raja M, & Bentivoglio AR (2012) Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson's Disease and other disorders. Curr Drug Saf, 7(1), 63-75.
181. Kringelbach ML, & Rolls ET (2003) Neural correlates of rapid reversal learning in a simple model of human social interaction. Neuroimage, 20(2), 1371-1383.
182. Clark L, Cools R, & Robbins TW (2004) The neuropsychology of ventral prefrontal cortex: Decision-making and reversal learning. Brain and Cognition, 55(1), 41-53.
183. Levin BE, Tomer R, & Rey GJ (1992) Cognitive impairments in Parkinson's disease. Neurol Clin, 10(2), 471-485.
184. Brown RG, & Marsden CD (1990) Cognitive function in Parkinson's disease: From description to theory. Trends Neurosci, 13(1), 21-29.
185. Poletti M, Cavedini P,&BonuccelliU(2011) Iowa gambling task in Parkinson's disease. J Clin Exp Neuropsychol, 33(4), 395-409.
186. Poletti M, & Bonuccelli U (2012) Orbital and ventromedial prefrontal cortex functioning in Parkinson's disease: Neuropsychological evidence. Brain and Cognition, 79(1), 23-33.
187. Carter CS, & van Veen V (2007) Anterior cingulate cortex and conflict detection: An update of theory and data. Cogn Affect Behav Neurosci, 7(4), 367-379.
188. Konishi S, Nakajima K, Uchida I, Kameyama M, Nakahara K, Sekihara K, & Miyashita Y (1998) Transient activation of inferior prefrontal cortex during cognitive set shifting. Nature Neuroscience, 1(1), 80-84.
189. Monchi O, Petrides M, Petre V, Worsley K, & Dagher A (2001)Wisconsin Card Sorting revisited: Distinct neural circuits participating in different stages of the task identified by event-related functional magnetic resonance imaging. The Journal of neuroscience: The official journal of the Society for Neuroscience, 21(19), 7733-7741.
190. Frank MJ, Loughry B, & O'Reilly RC (2001) Interactions between frontal cortex and basal ganglia in working memory: A computational model. Cogn Affect Behav Neurosci, 1(2), 137-160.
191. Raskin SA, Borod JC, & Tweedy J (1990) Neuropsychological aspects of Parkinson's disease. Neuropsychol Rev, 1(3), 185-221.
192. Pillon B, Deweer B, Vidailhet M, Bonnet AM, Hahn-Barma V, & Dubois B (1998) Is impaired memory for spatial location in Parkinson's disease domain specific or dependent on 'strategic' processes? Neuropsychologia, 36(1), 1-9.
193. Stocchi F, & Brusa L (2000) Cognition and emotion in different stages and subtypes of Parkinson's disease. Journal of Neurology, 247(Suppl 2), II114-II121.
194. Pagonabarraga J, Garcia-Sanchez C, Llebaria G, Pascual-Sedano B, Gironell A, & Kulisevsky J (2007) Controlled study of decision-making and cognitive impairment in Parkinson's disease. Mov Disord, 22(10), 1430-1435.
195. Flensborg Damholdt M, Shevlin M, Borghammer P, Larsen L, & Ostergaard K (2012) Clinical heterogeneity in Parkinson's disease revisited: A latent profile analysis. Acta Neurologica Scandinavica, 125(5), 311-318.
196. Gescheidt T, Czekoova K, Urbanek T, Marecek R, Mikl M, Kubikova R, Telecka S, Andrlova H, Husarova I, & Bares M (2012), Gambling Task in patients with earlyonset Parkinson's disease: Strategy analysis. Neurological sciences: Official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 33(6), 1329-1335.
197. Swainson R, Rogers RD, Sahakian BJ, SummersBA, Polkey CE, & Robbins TW (2000) Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: Possible adverse effects of dopaminergic medication. Neuropsychologia, 38(5), 596-612.
198. Cools R, Altamirano L, & D'Esposito M (2006) Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia, 44(10), 1663-1673.
199. Cools R, Barker RA, Sahakian BJ, & Robbins TW (2001) Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex, 11(12), 1136-1143.
200. Humphries MD, Khamassi M, & Gurney K (2012) Dopaminergic Control of the Exploration-Exploitation Trade-Off via the Basal Ganglia. Front Neurosci, 6, 9.
201. Euteneuer F, Schaefer F, Stuermer R, Boucsein W, Timmermann L, Barbe MT, Ebersbach G, Otto J, Kessler J, & Kalbe E (2009) Dissociation of decision-making under ambiguity and decision-making under risk in patients with Parkinson's disease:Aneuropsychological and psychophysiological study. Neuropsychologia, 47(13), 2882-2890.
202. Bechara A, Damasio AR, Damasio H, & Anderson SW (1994) Insensitivity to future consequences following damage to human prefrontal cortex. Cognition, 50(1-3), 7-15.
203. Bechara A, Damasio H, Damasio AR, & Lee GP (1999) Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 19(13), 5473-5481.
204. Mimura M, Oeda R, & Kawamura M (2006) Impaired decision-making in Parkinson's disease. Parkinsonism & Related Disorders, 12(3), 169-175.
205. Ibarretxe-Bilbao N, Junque C, Tolosa E, Marti MJ, Valldeoriola F, Bargallo N, & Zarei M (2009) Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson's disease. Eur J Neurosci, 30(6), 1162-1171.
206. Kobayakawa M, Koyama S, Mimura M, & Kawamura M (2008) Decision making in Parkinson's disease: Analysis of behavioral and physiological patterns in the Iowa gambling task.Movement Disorders: Official Journal of theMovement Disorder Society, 23(4), 547-552.
207. Perretta JG, Pari G,&Beninger RJ (2005) Effects of Parkinson disease on two putative nondeclarative learning tasks: Probabilistic classification and gambling. Cogn Behav Neurol, 18(4), 185-192.
208. Rossi M, Gerschcovich ER, de Achaval D, Perez-Lloret S, Cerquetti D, Cammarota A, Ines Nouzeilles M, Fahrer R, Merello M, & Leiguarda R (2010) Decision-making in Parkinson's disease patients with and without pathological gambling. Eur J Neurol, 17(1), 97-102.
209. Phillips LD,&EdwardsW(1966) Conservatism in a simple probability inference task. J Exp Psychol, 72(3), 346-354.
210. Cools R, Barker RA, Sahakian BJ, & Robbins TW (2003) L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia, 41(11), 1431-1441.
211. Torta DM, Castelli L, Zibetti M, Lopiano L, & Geminiani G (2009) On the role of dopamine replacement therapy in decision-making, working memory, and reward in Parkinson's disease: Does the therapy-dose matter? Brain and cognition, 71(2), 84-91.
212. Lejuez CW, Read JP, Kahler CW, Richards JB, Ramsey SE, Stuart GL, Strong DR, & Brown RA (2002) Evaluation of a behavioral measure of risk taking: The Balloon Analogue Risk Task (BART). J Exp Psychol Appl, 8(2), 75-84.
213. Fukunaga R, Brown JW, & Bogg T (2012) Decision making in the Balloon Analogue Risk Task (BART): Anterior cingulate cortex signals loss aversion but not the infrequency of risky choices. Cogn Affect Behav Neurosci, 12(3), 479-490.
214. Housden CR, O'Sullivan SS, Joyce EM, Lees AJ, & Roiser JP (2010) Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 35(11), 2155-2164.
215. Rømer Thomsen K, Joensson M, Lou HC, Møller A, Gross J, Kringelbach ML,&Changeux JP (2013) Altered paralimbic interaction in behavioral addiction. PNAS, 110(12), 4744-4749.
216. Macphee GJ, & Carson A (2013) Impulse control disorders in Parkinson disease: Is cognitive-behavioral therapy worth a wager? Neurology.
217. Okai D, Askey-Jones S, Samuel M, O'Sullivan SS, Chaudhuri KR, Martin A, Mack J, Brown RG, & David AS (2013) Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology, 80(9), 792-799.
218. Leroi I, HarbishettarV, Andrews M, McDonald K, Byrne EJ, & Burns A (2012) Carer burden in apathy and impulse control disorders in Parkinson's disease. International Journal of Geriatric Psychiatry, 27(2), 160-166.
219. Rabinak CA, & Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Archives of Neurology, 67(1), 58-63.
220. Bermejo PE, Ruiz-Huete C, & Anciones B (2010) Zonisamide in managing impulse control disorders in Parkinson's disease. Journal of Neurology, 257(10), 1682-1685.
221. Ivanco LS, & Bohnen NI (2005) Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: A single case study. Am J Ther, 12(5), 467-468.
222. Jankovic J, & Poewe W (2012) Therapies in Parkinson's disease. Current Opinion in Neurology, 25(4), 433-447.
223. Hicks CW, Pandya MM, Itin I, & Fernandez HH (2011) Valproate for the treatment of medication-induced impulsecontrol disorders in three patients with Parkinson's disease. Parkinsonism & Related Disorders, 17(5), 379-381.
224. Baarendse PJ, & Vanderschuren LJ (2012) Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats. Psychopharmacology (Berl), 219(2), 313-326.
225. Grant JE, Odlavg BL, Potenza MN, Hollander E, & Won Kim S (2010) Nalmafene in the treatment of pathological gambling: Multicentre, double-blind, placebo-controlled study. BJPsych, 197, 330-331.
226. Muller T (2012) Drug therapy in patients with Parkinson's disease. Transl Neurodegener, 1(1), 10.
227. Connolly BS,&Fox SH (2012) Drug treatments for the neuropsychiatric complications of Parkinson's disease. Expert Rev Neurother, 12(12), 1439-1449.